{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:47:16Z","timestamp":1771526836928,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Several interventional studies have evaluated the potential anti-Mullerian hormone (AMH)-reduction effect of metformin. However, the results are still contradictory. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of metformin on AMH in the women with with polycystic ovarian syndrome (PCOS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Scopus, PubMed\/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the AMH levels following metformin administration. Pooled weighted mean difference and 95% confidence intervals were achieved by random-effects model analysis for the best estimation of outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen studies with 484 participants\u2019 were included in this article. The pooled findings showed that AMH levels in the single arm clinical trials were significantly reduced (pooled WMD of -3.06 ng\/ml; 95% confidence interval [CI] -4.03 to -2.10; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) after use of metformin. Furthermore, compared to the control group, in randomized clinical trials, a reduced significant effect on AMH levels was observed following use of metformin (pooled WMD of -3.47 ng\/ml; 95% CI -7.14 to -0.19; <jats:italic>P<\/jats:italic>\u2009=\u20090.047). Furthermore, higher reduction in the AMH levels with a metformin dosage\u2009\u2264\u20091500\u00a0mg\/day and duration of treatment\u2009\u2264\u200912 weeks when compared to higher dosages and duration of intervention, observed in this meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, results this meta-analysis of clinical trials confirms the beneficial effect of the treatment with metformin in the reduction of the AMH levels in women.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-024-01570-z","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:48:22Z","timestamp":1711687702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of metformin on anti-mullerian hormone levels in women with polycystic ovarian syndrome: a systematic review and meta-regression analysis of randomized controlled trials with"],"prefix":"10.1186","volume":"24","author":[{"given":"Mehdi","family":"Mehdinezhad Roshan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hassan","family":"Sohouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elma","family":"Izze da Silva Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Hekmatdoost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"1\u20132","key":"1570_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0303-7207(94)90274-7","volume":"100","author":"JA Grootegoed","year":"1994","unstructured":"Grootegoed JA, Baarends WM, Themmen AP. Welcome to the family: the anti-m\u00fcllerian hormone receptor. Mol Cell Endocrinol. 1994;100(1\u20132):29\u201334. PubMed PMID: 8056154. eng.","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"1570_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/j.1600-0412.2012.01471.x","volume":"91","author":"AG Grynnerup","year":"2012","unstructured":"Grynnerup AG, Lindhard A, S\u00f8rensen S. The role of anti-M\u00fcllerian hormone in female fertility and infertility - an overview. Acta Obstet Gynecol Scand. 2012;91(11):1252\u201360. PubMed PMID: 22646322. eng.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12958-015-0134-9","volume":"13","author":"A Dumont","year":"2015","unstructured":"Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of Anti-M\u00fcllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol. 2015;13:137. PubMed PMID: 26691645. Pubmed Central PMCID: PMC4687350. Epub 20151221. eng.","journal-title":"Reprod Biol Endocrinol"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bpobgyn.2016.03.004","volume":"37","author":"P Bhide","year":"2016","unstructured":"Bhide P, Homburg R. Anti-M\u00fcllerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:38\u201345. PubMed PMID: 27103234. Epub 20160401. eng.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1570_CR5","doi-asserted-by":"crossref","unstructured":"Chhabra N, Malik S. Effect of insulin sensitizers on raised serum anti-mullerian hormone levels in Infertile women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018 Oct-Dec;11(4):348\u201352. PubMed PMID: 30787519. Pubmed Central PMCID: PMC6333035. eng.","DOI":"10.4103\/jhrs.JHRS_59_17"},{"key":"1570_CR6","unstructured":"Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. lippincott Williams & wilkins; 2005."},{"issue":"5","key":"1570_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ncpendmet0787","volume":"4","author":"A Dunaif","year":"2008","unstructured":"Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome\u2014a reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4(5):272\u201383.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"1570_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-022-01065-9","volume":"22","author":"W-W Yin","year":"2022","unstructured":"Yin W-W, Huang C-C, Chen Y-R, Yu D-Q, Jin M, Feng C. The effect of medication on serum anti-m\u00fcllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. BMC Endocr Disorders. 2022;22(1):1\u201314.","journal-title":"BMC Endocr Disorders"},{"issue":"1","key":"1570_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1.","journal-title":"Syst Reviews"},{"issue":"6543","key":"1570_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bmj.293.6543.355","volume":"293","author":"J Adams","year":"1986","unstructured":"Adams J, Polson D, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355\u20139.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1570_CR11","doi-asserted-by":"crossref","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handb Syst Reviews Interventions. 2019;205:28.","DOI":"10.1002\/9781119536604.ch8"},{"issue":"6","key":"1570_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3945\/an.116.013052","volume":"7","author":"L Schwingshackl","year":"2016","unstructured":"Schwingshackl L, Kn\u00fcppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, et al. Perspective: NutriGrade: a Scoring System to assess and judge the Meta-evidence of Randomized controlled trials and Cohort studies in Nutrition Research. Adv Nutr. 2016;7(6):994\u20131004. PubMed PMID: 28140319. eng.","journal-title":"Adv Nutr"},{"key":"1570_CR13","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org. 2011."},{"issue":"1","key":"1570_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"1570_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"1570_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"1","key":"1570_CR17","first-page":"31","volume":"10","author":"B Wiweko","year":"2017","unstructured":"Wiweko B, Susanto CA. The effect of metformin and cinnamon on serum anti-mullerian hormone in women having PCOS: a Double-blind, randomized, controlled trial. J Hum Reproductive Sci. 2017;10(1):31.","journal-title":"J Hum Reproductive Sci"},{"issue":"12","key":"1570_CR18","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.19082\/5969","volume":"9","author":"F Foroozanfard","year":"2017","unstructured":"Foroozanfard F, Samimi M, Almadani KH, Sehat M. Effect of metformin on the anti-M\u00fcllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Physician. 2017;9(12):5969.","journal-title":"Electron Physician"},{"issue":"5","key":"1570_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/cen.13304","volume":"86","author":"V Tagliaferri","year":"2017","unstructured":"Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, et al. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol. 2017;86(5):725\u201330.","journal-title":"Clin Endocrinol"},{"issue":"10","key":"1570_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1055\/s-0031-1286307","volume":"43","author":"\u0410 Tomova","year":"2011","unstructured":"Tomova \u0410, Deepinder F, Robeva R, Kirilov G, Mechandjiev Z, Kumanov P. Anti-M\u00fcllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res. 2011;43(10):723\u20137.","journal-title":"Horm Metab Res"},{"issue":"3","key":"1570_CR21","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.fertnstert.2012.07.771","volume":"98","author":"M Sauerbrun-Cutler","year":"2012","unstructured":"Sauerbrun-Cutler M, Lederman M, Keltz M, Lee M, Stein D. Serum anti-m\u00fcllerian hormone levels (AMH) decrease after metformin administration in women with both lean and overweight polycystic ovary syndrome (PCOS). Fertil Steril. 2012;98(3):S213.","journal-title":"Fertil Steril"},{"issue":"3","key":"1570_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/09513590.2012.736563","volume":"29","author":"AD Nascimento","year":"2013","unstructured":"Nascimento AD, Lara LAS, Rosa-e-Silva ACJS, Ferriani RA, Reis RM. Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(3):246\u20139.","journal-title":"Gynecol Endocrinol"},{"issue":"8","key":"1570_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/09513590.2010.507283","volume":"27","author":"D Panidis","year":"2011","unstructured":"Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-M\u00fcllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011;27(8):587\u201392.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1570_CR24","first-page":"462","volume":"5","author":"M Neagu","year":"2012","unstructured":"Neagu M, Cristescu C. Anti-M\u0171llerian hormone\u2013a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012;5(4):462.","journal-title":"J Med Life"},{"issue":"5","key":"1570_CR25","doi-asserted-by":"publisher","first-page":"E821","DOI":"10.1210\/jc.2010-1725","volume":"96","author":"D Romualdi","year":"2011","unstructured":"Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metabolism. 2011;96(5):E821\u20134.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"7","key":"1570_CR26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/humrep\/deh850","volume":"20","author":"T Piltonen","year":"2005","unstructured":"Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-M\u00fcllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820\u20136.","journal-title":"Hum Reprod"},{"issue":"1","key":"1570_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4274\/jcrpe.2338","volume":"8","author":"F Dursun","year":"2016","unstructured":"Dursun F, G\u00fcven A, Y\u0131ld\u0131z M. Assessment of anti-M\u00fcllerian hormone level in management of adolescents with polycystic ovary syndrome. J Clin Res Pediatr Endocrinol. 2016;8(1):55.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"5","key":"1570_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/aogs.12605","volume":"94","author":"HN Madsen","year":"2015","unstructured":"Madsen HN, Lauszus FF, Trolle B, Ingerslev HJ, T\u00f8rring N. Impact of metformin on anti-M\u00fcllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand. 2015;94(5):547\u201351.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"1570_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.fertnstert.2004.05.098","volume":"83","author":"R Fleming","year":"2005","unstructured":"Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum m\u00fcllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril. 2005;83(1):130\u20136.","journal-title":"Fertil Steril"},{"issue":"4","key":"1570_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/09513590.2010.487595","volume":"27","author":"F F\u00e1bregues","year":"2011","unstructured":"F\u00e1bregues F, Castelo-Branco C, Carmona F, Guimer\u00e1 M, Casamitjana R, Balasch J. The effect of different hormone therapies on anti-m\u00fcllerian hormone serum levels in anovulatory women of reproductive age. Gynecol Endocrinol. 2011;27(4):216\u201324.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1570_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-3-16","volume":"3","author":"A Falbo","year":"2010","unstructured":"Falbo A, Rocca M, Russo T, D\u2019Ettore A, Tolino A, Zullo F, et al. Serum and follicular anti-mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3(1):1\u20136.","journal-title":"J Ovarian Res"},{"issue":"6","key":"1570_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clbc.2013.08.012","volume":"13","author":"C Campagnoli","year":"2013","unstructured":"Campagnoli C, Berrino F, Venturelli E, Abb\u00e0 C, Biglia N, Brucato T, et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer. 2013;13(6):433\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1570_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079904125003278","volume":"20","author":"L Blonde","year":"2004","unstructured":"Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1570_CR34","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1210\/jc.2003-030727","volume":"88","author":"P Pigny","year":"2003","unstructured":"Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metabolism. 2003;88(12):5957\u201362.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"1570_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0015-0282(97)81417-3","volume":"67","author":"ME Fallat","year":"1997","unstructured":"Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. M\u00fcllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997;67(5):962\u20135.","journal-title":"Fertil Steril"},{"issue":"1","key":"1570_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1210\/jc.2003-030932","volume":"89","author":"JS Laven","year":"2004","unstructured":"Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metabolism. 2004;89(1):318\u201323.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"1\u20132","key":"1570_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0303-7207(02)00114-4","volume":"192","author":"PR Kezele","year":"2002","unstructured":"Kezele PR, Nilsson EE, Skinner MK. Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition. Mol Cell Endocrinol. 2002;192(1\u20132):37\u201343.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"1570_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1095\/biolreprod16.2.216","volume":"16","author":"BJ Gulyas","year":"1977","unstructured":"Gulyas BJ, Hodgen GD, Tullner WW, Ross GT. Effects of fetal or maternal hypophysectomy on endocrine organs and body weight in infant rhesus monkeys (Macaca mulatta): with particular emphasis on oogenesis. Biol Reprod. 1977;16(2):216\u201327.","journal-title":"Biol Reprod"},{"issue":"6","key":"1570_CR39","first-page":"774","volume":"18","author":"A Dunaif","year":"1997","unstructured":"Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774\u2013800.","journal-title":"Endocr Rev"},{"issue":"2","key":"1570_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/rep.1.01074","volume":"132","author":"PG Knight","year":"2006","unstructured":"Knight PG, Glister C. TGF-\u03b2 superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191\u2013206.","journal-title":"Reproduction"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01570-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:48:28Z","timestamp":1711687708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01570-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01570-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"22 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the research council and ethics committee Shahid Beheshti University of Medical Sciences, Tehran, Iran.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}